A panel of IgG1 b12 variants with selectively diminished or enhanced affinity for Fcγ receptors to define the role of effector functions in protection against HIV

Journal of Virology

Volumn 85, Issue 20, 2011, Pages 10572-10581

  Moldt, Brian ^a   Schultz, Niccole ^a   Dunlop, D Cameron ^a   Alpert, Michael D ^b   Harvey, Jackson D ^b   Evans, David T ^b   Poignard, Pascal ^a,c   Hessell, Ann J ^a,e   Burton, Dennis R ^a,d  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; FC RECEPTOR IIA; FC RECEPTOR IIIA; GLYCOPROTEIN GP 120; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G1 B12 ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN BINDING; ARTICLE; BINDING KINETICS; CELL ACTIVATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNITY; NATURAL KILLER CELL; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR AFFINITY; RECEPTOR BINDING; VIRUS INHIBITION; VIRUS NEUTRALIZATION; WILD TYPE;

ANIMALS; ANTIBODIES, NEUTRALIZING; CYTOTOXICITY, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIV ANTIBODIES; HUMANS; IMMUNOGLOBULIN G; KILLER CELLS, NATURAL; MACACA MULATTA; PHAGOCYTOSIS; PROTEIN BINDING; RECEPTORS, FC; RECOMBINATION, GENETIC; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; SURFACE PLASMON RESONANCE;

MACACA MULATTA; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

EID: 80055020243     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.05541-11     Document Type: Article

References (50)

1. Abela, I. A., L. Reynell, and A. Trkola. 2010. Therapeutic antibodies in HIV treatment-classical approaches to novel advances. Curr. Pharm. Des. 16: 3754-3766.
2. Ackerman, M. E., et al. 2011. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J. Immunol. Methods 366:8-19.
3. Alter, G., J. M. Malenfant, and M. Altfeld. 2004. CD107a as a functional marker for the identification of natural killer cell activity. J. Immunol. Methods 294:15-22.
4. Awan, F. T., et al. 2010. CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. Blood 115:1204-1213.
5. Baldridge, J. R., and M. J. Buchmeier. 1992. Mechanisms of antibodymediated protection against lymphocytic choriomeningitis virus infection: mother-to-baby transfer of humoral protection. J. Virol. 66:4252-4257.
6. Banks, N. D., N. Kinsey, J. Clements, and J. E. Hildreth. 2002. Sustained antibody-dependent cell-mediated cytotoxicity (ADCC) in SIV-infected macaques correlates with delayed progression to AIDS. AIDS Res. Hum. Retroviruses 18:1197-1205.
7. Burton, D. R., et al. 1994. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266:1024-1027.
8. Cardarelli, P. M., et al. 2010. A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies. Cancer Immunol. Immunother. 59:257-265.
9. Cartron, G., et al. 2002. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99:754-758.
10. Desjarlais, J. R., G. A. Lazar, E. A. Zhukovsky, and S. Y. Chu. 2007. Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective. Drug Discov. Today 12:898-910.
11. Forthal, D. N., et al. 2010. Fc-glycosylation influences Fcgamma receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12. J. Immunol. 185:6876-6882.
12. Forthal, D. N., P. B. Gilbert, G. Landucci, and T. Phan. 2007. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J. Immunol. 178:6596-6603.
13. Forthal, D. N., et al. 2006. Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells. J. Virol. 80:9217-9225.
14. Forthal, D. N., G. Landucci, and E. S. Daar. 2001. Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J. Virol. 75:6953-6961.
15. Forthal, D. N., and C. Moog. 2009. Fc receptor-mediated antiviral antibodies. Curr. Opin. HIV AIDS 4:388-393.
16. Forthal, D. N., et al. 2007. FcγRIIa genotype predicts progression of HIV infection. J. Immunol. 179:7916-7923.
17. Gomez-Roman, V. R., et al. 2005. Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J. Immunol. 174:2185-2189.
18. Hayashida, I., et al. 1982. Mechanism of antibody-mediated protection against herpes simplex virus infection in athymic nude mice: requirement of Fc portion of antibody. Microbiol. Immunol. 26:497-509.
19. Hessell, A. J., et al. 2007. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449:101-104.
20. Hessell, A. J., et al. 2009. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med. 15:951-954.
21. Hessell, A. J., et al. 2009. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 5:e1000433.
22. Hezareh, M., A. J. Hessell, R. C. Jensen, J. G. van de Winkel, and P. W. Parren. 2001. Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1. J. Virol. 75:12161-12168.
23. Huber, V. C., J. M. Lynch, D. J. Bucher, J. Le, and D. W. Metzger. 2001. Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J. Immunol. 166:7381-7388.
24. Jefferis, R. 2009. Glycosylation as a strategy to improve antibody-based therapeutics. Nat. Rev. Drug Discov. 8:226-234.
25. Karnasuta, C., et al. 2005. Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine 23:2522-2529.
26. Klein, J. S., A. Webster, P. N. Gnanapragasam, R. P. Galimidi, and P. J. Bjorkman. 2010. A dimeric form of the HIV-1 antibody 2G12 elicits potent antibody-dependent cellular cytotoxicity. AIDS 24:1633-1640.
27. Lazar, G. A., et al. 2006. Engineered antibody Fc variants with enhanced effector function. Proc. Natl. Acad. Sci. U. S. A. 103:4005-4010.
28. Leaman, D. P., H. Kinkead, and M. B. Zwick. 2010. In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1. J. Virol. 84:3382-3395.
29. Li, M., et al. 2005. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccineelicited neutralizing antibodies. J. Virol. 79:10108-10125.
30. Mascola, J. R. 2009. The cat and mouse of HIV-1 antibody escape. PLoS Pathog. 5:e1000592.
31. Mascola, J. R. 2002. Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1. Vaccine 20:1922-1925.
32. Mascola, J. R., et al. 2000. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6:207-210.
33. Mathews, J. H., J. T. Roehrig, and D. W. Trent. 1985. Role of complement and the Fc portion of immunoglobulin G in immunity to Venezuelan equine encephalomyelitis virus infection with glycoprotein-specific monoclonal antibodies. J. Virol. 55:594-600.
34. McKendall, R. R. 1985. IgG-mediated viral clearance in experimental infection with herpes simplex virus type 1: role for neutralization and Fc-dependent functions but not C' cytolysis and C5 chemotaxis. J. Infect. Dis. 151: 464-470.
35. Myszka, D. G. 1999. Improving biosensor analysis. J. Mol. Recognit. 12:279-284.
36. Nimmerjahn, F., and J. V. Ravetch. 2008. Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 8:34-47.
37. Parren, P. W., and D. R. Burton. 2001. The antiviral activity of antibodies in vitro and in vivo. Adv. Immunol. 77:195-262.
38. Parren, P. W., et al. 2001. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75:8340-8347.
39. Peressin, M., et al. 2011. HIV-1 replication in Langerhans and interstitial dendritic cells is inhibited by neutralizing and Fc-mediated inhibitory antibodies. J. Virol. 85:1077-1085.
40. Perez, L. G., M. R. Costa, C. A. Todd, B. F. Haynes, and D. C. Montefiori. 2009. Utilization of immunoglobulin G Fc receptors by human immunodeficiency virus type 1: a specific role for antibodies against the membraneproximal external region of gp41. J. Virol. 83:7397-7410.
41. Reichert, J. M. 2010. Antibodies to watch in 2010. MAbs 2:84-100.
42. Rerks-Ngarm, S., et al. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361:2209-2220.
43. Richards, J. O., et al. 2008. Optimization of antibody binding to Fcgamma-RIIa enhances macrophage phagocytosis of tumor cells. Mol. Cancer Ther. 7:2517-2527.
44. Saphire, E. O., et al. 2001. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science 293:1155-1159.
45. Shields, R. L., et al. 2001. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J. Biol. Chem. 276:6591-6604.
46. Tebo, A. E., P. G. Kremsner, and A. J. Luty. 2002. Fcgamma receptormediated phagocytosis of Plasmodium falciparum-infected erythrocytes in vitro. Clin. Exp. Immunol. 130:300-306.
47. Trkola, A., et al. 2005. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat. Med. 11:615-622.
48. Trkola, A., J. Matthews, C. Gordon, T. Ketas, and J. P. Moore. 1999. A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor. J. Virol. 73:8966-8974.
49. Veazey, R. S., et al. 2003. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat. Med. 9:343-346.
50. Yagita, M., et al. 2000. A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation. Leukemia 14:922-930.